MaxCyte, Inc. (LON:MXCT) Insider Sells £22,050 in Stock

MaxCyte, Inc. (LON:MXCT) insider John Johnston sold 5,000 shares of the company’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of GBX 441 ($5.54), for a total value of £22,050 ($27,680.14).

MaxCyte Trading Up 2.8 %

Shares of LON:MXCT opened at GBX 333 ($4.18) on Friday. The company has a market cap of £346.75 million, a P/E ratio of -1,137.93 and a beta of 1.04. The company has a debt-to-equity ratio of 8.07, a current ratio of 10.65 and a quick ratio of 14.38. MaxCyte, Inc. has a 1 year low of GBX 180 ($2.26) and a 1 year high of GBX 440 ($5.52). The stock’s fifty day moving average price is GBX 357.30 and its 200-day moving average price is GBX 333.23.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.